High On-Treatment Platelet Reactivity in Peripheral Arterial Disease: A Pilot Study to Find the Optimal Test and Cut Off Values

European Journal of Vascular and Endovascular Surgery

Volumn 52, Issue 2, 2016, Pages 198-204

  Leunissen, T C ^a   Peeters Weem, S M O ^a   Urbanus, R T ^a   den Ruijter, H M ^a   Moll, F L ^a   Asselbergs, F W ^a,b,c   de Borst, G J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b INTERUNIVERSITY CARDIOLOGY INSTITUTE OF THE NETHERLANDS   (Netherlands)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiplatelet drug resistance; Antiplatelet therapy; Clopidogrel; Peripheral artery disease; Platelet inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; FIBRINOGEN; PADGEM PROTEIN; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DUAL ANTIPLATELET THERAPY; EXPLORATORY RESEARCH; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; OBSERVATIONAL STUDY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BINDING; REFERENCE VALUE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION ANALYZER; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; COMBINATION DRUG THERAPY; PERIPHERAL ARTERIAL DISEASE; PHYSIOLOGY; PROCEDURES; STANDARDS; THROMBOCYTE;

AGED; ASPIRIN; BLOOD PLATELETS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; PERIPHERAL ARTERIAL DISEASE; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TICLOPIDINE;

EID: 84969731113     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2016.04.019     Document Type: Article

References (36)

1. 1 Norgren, L., Hiatt, W.R., Dormandy, J.A., Nehler, M.R., Harris, K.A., Fowkes, F.G.R., Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45:Suppl. S(Tasc II) (2007), S5–S67.
2. 2 Schillinger, M., Sabeti, S., Loewe, C., Dick, P., Amighi, J., Mlekusch, W., et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 354:18 (2006), 1879–1888.
3. 3 Krankenberg, H., Schlüter, M., Steinkamp, H.J., Bürgelin, K., Scheinert, D., Schulte, K.-L., et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 116:3 (2007), 285–292.
4. 4 Dick, F., Ricco, J.-B., Davies, A.H., Cao, P., Setacci, C., de Donato, G., et al. Chapter VI: follow up after revascularisation. Eur J Vasc Endovasc Surg 42:Suppl. 2 (2011), S75–S90.
5. 5 Laird, J.R., Katzen, B.T., Scheinert, D., Lammer, J., Carpenter, J., Buchbinder, M., et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelve-month results from the RESILIENT randomized trial. Circ Cardiovasc Interv 3:3 (2010), 267–276.
6. 6 Rastan, A., Krankenberg, H., Baumgartner, I., Blessing, E., Müller-Hülsbeck, S., Pilger, E., et al. Stent placement versus balloon angioplasty for the treatment of obstructive lesions of the popliteal artery: a prospective, multicenter, randomized trial. Circulation 127:25 (2013), 2535–2541.
7. 7 Antithrombotic Trialists' Collaboration, Trialists A, Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:7329 (2002), 71–86.
8. 8 Wisman, P.P., Roest, M., Asselbergs, F.W., de Groot, P.G., Moll, F.L., van der Graaf, Y., et al. Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis. J Thromb Haemost 12:5 (2014), 736–747.
9. 9 Spiliopoulos, S., Pastromas, G., Katsanos, K., Kitrou, P., Karnabatidis, D., Siablis, D., Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol 61:24 (2013), 2428–2434.
10. 10 Pastromas, G., Spiliopoulos, S., Katsanos, K., Diamantopoulos, A., Kitrou, P., Karnabatidis, D., et al. Clopidogrel responsiveness in patients undergoing peripheral angioplasty. Cardiovasc Intervent Radiol 36:6 (2013), 1493–1499.
11. 11 Kliger, C., Babaev, A., Shah, B., Feit, F., Slater, J., Attubato, M., Dual antiplatelet therapy responsiveness in patients undergoing percutaneous revascularization for peripheral arterial occlusive disease. J Am Coll Cardiol, 59(13), 2012, E2049.
12. 12 Scott, S.A., Sangkuhl, K., Gardner, E.E., Stein, C.M., Hulot, J.-S., Johnson, J.A., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther 90:2 (2011), 328–332.
13. 13 Serebruany, V., Cherala, G., Williams, C., Surigin, S., Booze, C., Kuliczkowski, W., et al. Association of platelet responsiveness with clopidogrel metabolism: role of compliance in the assessment of “resistance”. Am Heart J 158:6 (2009), 925–932.
14. 14 Mangiacapra, F., Patti, G., Peace, A., Gatto, L., Vizzi, V., Ricottini, E., et al. Comparison of platelet reactivity and peri-procedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention. Am J Cardiol 106:5 (2010), 619–623.
15. 15 Morel, O., Muller, C., Jesel, L., Moulin, B., Hannedouche, T., Impaired platelet P2Y12 inhibition by thienopyridines in chronic kidney disease: mechanisms, clinical relevance and pharmacological options. Nephrol Dial Transplant 28:8 (2013), 1994–2002.
16. 16 Gurbel, P.A., Bliden, K.P., Logan, D.K., Kereiakes, D.J., Lasseter, K.C., White, A., et al. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the paradox study. J Am Coll Cardiol 62:6 (2013), 505–512.
17. 17 Peeters Weem, S.M.O., Leunissen, T.C., Teraa, M., Vonken, E.J., de Borst, G.J., Moll, F.L., Personalized antiplatelet therapy following endovascular revascularization in peripheral artery occlusive disease: a novel concept. EJVES Short Rep 29 (2015), 11–17.
18. 18 Price, M.J., Berger, P.B., Teirstein, P.S., Tanguay, J.-F., Angiolillo, D.J., Spriggs, D., et al. Standard- vs high dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305:11 (2011), 1097–1105.
19. 19 Montalescot, G., Rangé, G., Silvain, J., Bonnet, J.L., Boueri, Z., Barthélémy, O., et al. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: a landmark analysis of the ARCTIC study. Circulation 129:21 (2014), 2136–2143.
20. 20 Siller-Matula, J.M., Francesconi, M., Dechant, C., Jilma, B., Maurer, G., Delle-Karth, G., et al. Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. Int J Cardiol 167:5 (2013), 2018–2023.
21. 21 Bonello, L., Camoin-Jau, L., Arques, S., Boyer, C., Panagides, D., Wittenberg, O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance. A multicenter randomized prospective study. J Am Coll Cardiol 51:14 (2008), 1404–1411.
22. 22 Valgimigli, M., Campo, G., de Cesare, N., Meliga, E., Vranckx, P., Furgieri, A., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel group. Circulation 119:25 (2009), 3215–3222.
23. 23 Price, M.J., Endemann, S., Gollapudi, R.R., Valencia, R., Stinis, C.T., Levisay, J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:8 (2008), 992–1000.
24. 24 Accumetrics San Diego, VerfiyNow P2Y12 platelet reactivity test – instructions for use. 2013.
25. 25 Lee, D.H., Arat, A., Morsi, H., Shaltoni, H., Harris, J.R., Mawad, M.E., Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single center experience. Am J Neuroradiol 29:7 (2008), 1389–1394.
26. 26 Barragan, P., Bouvier, J.L., Roquebert, P.O., Macaluso, G., Commeau, P., Comet, B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 59:3 (2003), 295–302.
27. 27 Campo, G., Fileti, L., Valgimigli, M., Tebaldi, M., Cangiano, E., Cavazza, C., et al. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 30:3 (2010), 319–331.
28. 28 Karnabatidis, D., Spiliopoulos, S., Pastromas, G., Kitrou, P., Christeas, N., Katsanos, K., et al. Prevalence of nonresponsiveness to aspirin in patients with symptomatic peripheral arterial disease using true point of care testing. Cardiovasc Intervent Radiol 37:3 (2014), 631–638.
29. 29 Price, M.J., Coleman, J.L., Steinhubl, S.R., Wong, G.B., Cannon, C.P., Teirstein, P.S., Onset and offset of platelet inhibition after high dose clopidogrel loading and standard daily therapy measured by a point-of-care assay in healthy volunteers. Am J Cardiol 98:5 (2006), 681–684.
30. 30 Connors, G., Todoran, T.M., Engelson, B.A., Sobieszczyk, P.S., Eisenhauer, A.C., Kinlay, S., Percutaneous revascularization of long femoral artery lesions for claudication. Catheter Cardiovasc Interv 77:7 (2011), 1055–1062.
31. 31 Thukkani, A.K., Kinlay, S., Hospital, M.B., Divisions, C., Endovascular intervention for peripheral artery disease. Circ Res 116:9 (2015), 1599–1613.
32. 32 Bal Dit Sollier, C., Berge, N., Boval, B., Dubar, M., Drouet, L., Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 104:3 (2010), 571–581.
33. 33 Varenhorst, C., James, S., Erlinge, D., Braun, O.Ö., Brandt, J.T., Winters, K.J., et al. Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 157:3 (2009), 562.e1–562.e9.
34. 34 Joseph, P., Teo, K., Optimal medical therapy, lifestyle intervention, and secondary prevention strategies for cardiovascular event reduction in ischemic heart disease. Curr Cardiol Rep 13:4 (2011), 287–295.
35. 35 Simmons, B.B., Yeo, A., Fung, K., Current guidelines on antiplatelet agents for secondary prevention of noncardiogenic stroke: an evidence based review. Postgrad Med 122:2 (2010), 49–53.
36. 36 Dridi, N.P., Johansson, P.I., Clemmensen, P., Stissing, T., Radu, M.D., Qayyum, A., et al. Prasugrel or double-dose clopidogrel to overcome clopidogrel low-response – the TAILOR (Thrombocytes and IndividuaLization of ORal antiplatelet therapy in percutaneous coronary intervention) randomized trial. Platelets 7104:August (2013), 1–7.